Company Overview and News
PERTH, Australia, April 11, 2018 (GLOBE NEWSWIRE) -- Bannerman Resources Limited (ASX:BMN) (NSX:BMN) (Bannerman or the Company) is pleased to announce that the Etango Membrane Study has been completed successfully, delivering substantial reagent/operating cost reductions along with forecast capital savings, the final quantum of which is to be confirmed in the Etango Definitive Feasibility Study Update (DFS Update).
Bannerman Resources Limited (ASX:BMN) has successfully completed the initial test work phase of the membrane study for its proposed Etango Uranium Mine located in Namibia.
Brandon Munro, chief executive of Bannerman Resources Ltd (ASX:BMN; NSX:BMN), talks Proactive through the details of their recently completed Etango Processing Optimisation Study (Processing OS).
Bannerman Resources Ltd (ASX:BMN; NSX:BMN) continues to maintain its Etango Uranium Project in Namabia at the forefront of the global uranium development pipeline. Bannerman has now revealed details of the successfully completed Etango Processing Optimisation Study (Processing OS), by its independent technical consultants, AMEC Foster Wheeler.
Bannerman Resources (ASX:BMN) has been granted a Mineral Deposit Retention Licence with a five year extendable term for its 95%-owned Etango Uranium Project located in Namibia.
While the uranium market still remains challenging, forward demand continues to strengthen and Bannerman keep progressing on its Etango uranium project.
While the uranium market still remains challenging, forward demand continues to strengthen and Bannerman keeps progressing on its Etango uranium project.
Bannerman Resources Ltd (ASX:BMN) has had its Exclusive Prospecting Licence 3345 renewed by the Namibian Ministry of Mines and Energy until the 25th April 2019.
PERTH, AUSTRALIA--(Marketwired - July 27, 2017) - Bannerman Resources Limited (ASX:BMN)(NAMIBIAN:BMN) ("Bannerman" or "the Company") is pleased to report on a productive June quarter.
PERTH, AUSTRALIA--(Marketwired - April 28, 2017) - Bannerman Resources Limited (ASX:BMN)(NAMIBIAN:BMN) ("Bannerman" or "the Company") is pleased to report on a successful March quarter that positions the Company well within an environment of improving uranium sector sentiment.
Bannerman Resources (ASX:BMN) has appointed former managing director of Rössing Uranium Mine in Namibia to its board of directors. Leech will sit on the board as a non-executive director and chairman of the company’s Namibian subsidiary. 333 He was Managing Director of the Rössing Uranium Mine in Namibia for six years until retiring in 2011. Prior to that he served as Rössing’s chief financial officer and in other executive positions within the Rio Tinto Group.
Bannerman Resources (ASX:BMN; NSX:BMN) key shareholder, Resource Capital Fund, has further increased its position in the company and now holds a 33.58% stake.
2018-04-25 - Asif
Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...
2018-04-25 - Asif
Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...
2018-04-23 - Asif
Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...